Agreed Viking...at this share price IPCI's currently priced for total and complete failure with this paltry 30 million dollar market cap...especially when 1 considers the fact that with the full scale launch of SeroquelXR by Mallinkrodt a couple of months ago that IPCI's calendar year revenues are approximately $20M now with a $13M per annum burn rate...and if either already partnered MNK ANDA finally gets FDA approved or IPCI secures a deal on Rexista or Regabatin those numbers immediately shoot higher.
Market Data 
Markets 
AI
